Biologic therapy for advanced breast cancer: recent advances and future directions

Paolo Tarantino\textsuperscript{a,b}, Stefania Morganti\textsuperscript{a,b} and Giuseppe Curiglano\textsuperscript{a,b}

\textsuperscript{a}European Institute of Oncology IRCCS, Milan, Italy; \textsuperscript{b}University of Milan, Milan, Italy

\textbf{ABSTRACT}

\textbf{Introduction:} Advanced breast cancer (ABC) is a leading cause of mortality, morbidity, and disability in women worldwide. For decades, treatment of ABC has relied on chemotherapy and endocrine treatments (ET), until HER2 was recognized as a ‘druggable’ target in the 1990s. Thereafter, various anti-HER2 drugs have been approved for the HER2-positive subtype, but only in the last few years, biologic agents targeting different pathways have entered the therapeutic arsenal of luminal and triple-negative cancers.

\textbf{Areas covered:} The purpose of the present review is to recapitulate the most promising novel biologic agents being developed for the treatment of ABC. New drugs for all breast cancer subtypes are discussed, as well as some potential future directions in ABC treatment.

\textbf{Expert opinion:} Several biologic drugs have been recently approved, revolutionizing ABC treatment algorithms: key examples are CDK4/6-inhibitors and the PI3K-inhibitor alpelisib for endocrine-positive ABC; atezolizumab for triple-negative cancers; two PARP-inhibitors for HER2-negative germinal BRCA-mutated cancers. Additionally, multiple drugs are demonstrating activity in late-phase clinical trials for all subtypes. While some of these represent pharmacological evolutions of previously approved drugs, some others might pave the way for new paradigms in ABC, challenging both its classification and current treatment algorithms.

1. Introduction

For decades, the treatment of advanced breast cancer (ABC) has predominantly consisted of traditional chemotherapies and endocrine treatments (ET). One relevant step forward was achieved in the 1990s, with the development and approval of the first biological agent, the anti-HER2 monoclonal antibody (mAb) trastuzumab [1]. Since then, several other anti-HER2 agents have been approved for the subgroup of HER2-positive ABC [2], while treatment of luminal HER2-negative and triple-negative cancers has kept consisting mainly of ET and chemotherapies. However, in the last few years, various new biological agents have entered the clinical practice in all subgroups of breast cancer (BC) (Figure 1). Three CDK4/6-inhibitors have been approved for the treatment of hormone receptor-positive ABC, showing to improve overall survival (OS) in this population [3–5]. Alpelisib has been approved for PIK3CA-mutated luminal ABC, in combination with ET [6,7]. The PARP-inhibitors olaparib and talazoparib have been approved for the treatment of HER2-negative germinal BRCA1/2-mutated (gBRCA-mut) ABC, regardless of hormone receptor expression, based on the benefit showed by two independent randomized controlled phase 3 clinical trials. Finally, the anti-PDL1 mAb atezolizumab has been positioned in the management of PDL1-positive advanced triple-negative breast cancer (TNBC). Drug development in this field has kept increasing its pace, and multiple highly active therapies are under study for the treatment of all ABC subgroups. The purpose of the present review is to recapitulate the most promising biological agents currently under early- and late-stage development and to underline the future directions in which ABC drug development is moving.

2. Hormone receptor-positive breast cancer

Estrogen receptor (ER) represents the first target discovered in the history of breast cancer [8]. Since the approval of tamoxifen in the 1970s, several ET have been added in the therapeutic armamentarium of luminal BC, including Selective Estrogen Receptor Modulators (SERMs), Selective Estrogen Receptor Downregulators (SERDs), and Aromatase Inhibitors (AIs) [9].

These agents have represented the cornerstone of luminal ABC treatment for decades, prolonging survival and sparing toxicity of chemotherapy to many women. Despite this fact, almost all ABCs ultimately lose responsiveness to hormonal treatments, and many efforts are ongoing to identify strategies to overcome this resistance.

Activation of alternative intracellular pathways is a recognized resistance mechanism to ET [10]. Several different biological agents targeting these pathways have demonstrated to reverse endocrine sensitivity when combined to hormonal drugs.

2.1. CDK 4/6 inhibitors

CDK4/6-inhibitors are selective inhibitors of cyclin-dependent kinases 4 and 6, enzymes directly involved in the regulation of cell cycle transition from G1- to S-phase. When combined with...
fulvestrant or AIs, these agents have demonstrated to improve treatment outcomes, with a favorable toxicity profile. The MONALEESA-2 [11,12], PALOMA-2 [13,14] and MONARCH-3 [15,16] trials, respectively, tested ribociclib, palbociclib, and abemaciclib in combination with AIs as first-line treatment for luminal BC. Similarly, the PALOMA-3 [5,17] and MONARCH-2 [18] trials combined palbociclib and abemaciclib with fulvestrant in patients who had previously progressed on ET alone, while the MONALEESA-3 study tested the combination of ribociclib and fulvestrant in both treatment-naive and women progressed to up to one line of ET [19]. All of these studies reached the primary endpoint, with a significant PFS increase, and CDK4/6-inhibitors + ET became standard of care for luminal ABC as both first-line treatment or after progression, and CDK4/6-inhibitors + ET became standard of care for luminal ABC as both first-line treatment or after progression.

As more genetic alterations become actionable, molecular profiling of ABC becomes increasingly important for the optimal selection of treatments. Biologic treatments inevitably increase treatment costs, and a major challenge in the future will be ensuring optimal accessibility to novel treatments in developing countries.

2.2. PI3K/AKT/mTOR pathway

The PI3K/AKT/mTOR pathway is frequently deregulated in BC [23]. Drugs targeting this pathway have been deeply investigated, with contradictory results.

Everolimus, an mTOR-inhibitor, is the first biological agent approved for luminal ABC. The BOLERO-2 [24] trial showed a PFS improvement with the combination of exemestane and everolimus versus exemestane alone, with a median PFS (mPFS) of 6.9 versus 2.8 months (hazard ratio [HR] 0.43; 95% confidence interval [CI], 0.35–0.54; p < 0.001), even if toxicity was higher in the experimental arm. In particular, treatment with everolimus resulted in a higher rate of grade 3–4 stomatitis, anemia, hyperglycemia, and pneumonitis. Due to the challenging toxicity profile, the compound is still only partially implemented in clinical practice.

Alpelisib is an oral α-selective inhibitor of PI3K. The phase 3 SOLAR-1 [6] trial compared the combination of fulvestrant ± alpelisib in patients with ET-pretreated luminal ABC. mPFS was significantly higher with the combination therapy (11 vs 5.7 months; HR 0.65; 95% CI, 0.50 to 0.85; p < 0.001) in patients with PI3KCA-mutated tumors, whereas this advantage was not observed for PI3KCA-wild type tumors. Most frequent ≥G3 AEs were hyperglycemia (36.6% vs 0.7% in experimental vs standard arm), rash (20.1% vs 0.3%), and diarrhea (6.7% vs 0.3%). The results of this trial led to alpelisib FDA-approval for PI3KCA-mutated luminal ABC, whereas approval is still pending in Europe.

Since only a minority of patients enrolled in the SOLAR-1 was pretreated with CDK4/6-inhibitors (6%), the BYLieve trial...
<table>
<thead>
<tr>
<th>Trial – NCT</th>
<th>Phase</th>
<th>Estimated enrollment</th>
<th>Study population</th>
<th>Study arms</th>
<th>Primary endpoint</th>
<th>CT.gov status</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03238196</td>
<td>I</td>
<td>32</td>
<td>ER+/HER2-/FGFR-amplified ABC; pretreated (min 1 max 2 lines); no prior treatment with CDK4/6i allowed</td>
<td>Palbociclib + fulvestrant + erdafitinib</td>
<td>Safety</td>
<td>Recruiting</td>
</tr>
<tr>
<td>NCT03147287</td>
<td>II</td>
<td>220</td>
<td>ER+/HER2- ABC progressing on/after CDK4/6i plus ET</td>
<td>Fulvestrant vs Palbociclib + fulvestrant</td>
<td>PFS</td>
<td>Recruiting</td>
</tr>
</tbody>
</table>
| NCT02599714         | I     | 54                   | ER+/HER2- ABC who have progressed to AIs (no prior treatment with CDK4/6i or everolimus or others PI3K-
mTOR inhibitors allowed in part B) | Palbociclib + fulvestrant + avelumab                                      | Safety           | Recruiting    |
| NCT03377101         | II    | NA                   | ER+/HER2- ABC resistant to ET (no prior treatment with CDK4/6i or fulvestrant or PI3K1i allowed in part II) | Palbociclib + fulvestrant + vistusertib                                    | PFS              | Recruiting    |
| NCT03685331         | I/II  | 54                   | BRCA-mutated ER+/HER2- ABC as 1st-3rd line of therapy (no prior treatment with CDK4/6i or PARPi allowed) | Palbociclib + fulvestrant + copanlisib                                     | Safety           | Recruiting    |
| NCT04060822         | I     | 370                  | ER+/HER2- ABC progressing on adjuvant/1st line ET (no prior treatment with CT or SERD or PI3K/AKT/ mTOR-pathway inhibitors allowed) | Palbociclib + fulvestrant + ipataserib vs Palbociclib + fulvestrant         | PFS              | Recruiting    |
| NCT02871791         | I/II  | 32                   | ER+/HER2- ABC progressing to CDK4/6i and relapsing/progressing on AIs (as adjuvant therapy or for ABC) | Palbociclib + fulvestrant + everolimus                                     | Safety, CBR      | Recruiting    |
| NCT03854903         | I     | 18                   | ER+/HER2- ABC refractory to CDK4/6i plus AI                                                         | Palbociclib + fulvestrant + bosutinib                                      | Safety, ORR      | Recruiting    |
| NCT02684632         | I     | 148                  | ER+/HER2- ABC as 1st-3rd line of therapy (depending on study arm; previous ET for ABC allowed in arm B and C; previous CDK4/6i allowed in arm C) | Palbociclib + letrozole + bosutinib                                       | Recruiting       |               |
| NCT03128619         | I     | 102                  | ER+/HER2- ABC as 1st line of therapy                                                                 | Palbociclib + letrozole + venetoclax                                      | Safety           | Recruiting    |
| NCT03900884         | I     | 36                   | ER+/HER2-/BCL2+ABC as 1st-3rd line of therapy (prior CDK4/6i or venetoclax not allowed)               | Palbociclib + letrozole + pembrolium                                     | Safety           | Not yet recruiting |
| NCT02778658         | II    | 22                   | ER+/HER2- ABC as 1st line of therapy                                                                 | Palbociclib + letrozole + venetoclax                                      | Safety           | Recruiting    |
| NCT13959891         | I     | 60                   | ER+/HER2- ABC progressing on at least 1 line of therapy (prior CDK4/6i or mTORi or PI3K1i allowed; prior AKTi not allowed) | Palbociclib + letrozole + pembrolium                                     | Safety           | Recruiting    |
| NCT03685591         | I     | 15                   | ER+/HER2- ABC progressing on at least 2 lines of therapy, including a CDK4/6i                         | Palbociclib + letrozole + GDC-007 or Palbociclib + letrozole + PF-06595229 | Safety           | Recruiting    |
| NCT03060172         | I     | 236                  | ER+/HER2-/PI3K-mutant ABC (prior CDK4/6i allowed or not depending on arm; prior PI3K1i not allowed; maximum 1 line of CT allowed) | Palbociclib + letrozole + GDC-007 or Palbociclib + letrozole + GDC-007 or Palbociclib + letrozole + GDC-007 + metformin | Safety           | Recruiting    |
| NCT02154776         | I     | 13                   | ER+/HER2- ABC (prior CDK4/6i or PI3K1i not allowed). No prior treatment for ABC allowed in the dose-
expansion phase.                                                                                                      | Ribociclib + letrozole + buparlisib                                      | Safety           | Completed     |
| NCT02732119         | I/II  | 107                  | ER+/HER2- ABC progressing on CDK4/6i + ET                                                            | Ribociclib + everolimus + exemestane                                      | Safety, CBR      | Recruiting    |
| NCT02088684         | I     | 70                   | ER+/HER2- ABC (unlimited lines of ET and up to 2 lines of CT allowed)                               | Ribociclib + fulvestrant + BKM1200 or Ribociclib + fulvestrant + alpelisib | Safety           | Recruiting    |
| NCT01857193         | I     | 132                  | ER+/HER2- ABC (prior CDK4/6i allowed or not depending on study group; up to 1 line of CT allowed)    | Ribociclib + everolimus + exemestane                                     | Safety           | Recruiting    |
| NCT03294694         | I     | 60                   | ER+/HER2- ABC (prior CDK4/6i or prior fulvestrant or prior IT not allowed in the dose expansion phase) | Ribociclib + exemestane                                                  | Safety           | Recruiting    |
| NCT03939897         | I     | 194                  | ER+/HER2- ABC (no maximum lines of ET; no more than 1 line of CT; prior fulvestrant and CDK4/6i allowed only in phase I) | Ribociclib + fulvestrant + spatralizumab                                   | Safety           | Recruiting    |
| NCT01057133*        | I     | 198                  | ER+/HER2- ABC progressing on ET, including at least one AI (prior CDK4/6i and prior CT not allowed)   | Abemaciclib + fulvestrant + copanlisib                                    | Safety, PFS      | Not yet recruiting |
| NCT03099174         | I     | 148                  | ER+/HER2- ABC (up to 2 lines of CT allowed; no prior CDK4/6i allowed except for cohort F)           | Abemaciclib + ET + xentuxumab                                           | Safety, ORR, PFS | Recruiting    |

*Only the study arm combining CDK4/6i with biological agent is here considered.

ABC – advanced breast cancer; AI – aromatase inhibitors; CBR – clinical benefit rate; CT – chemotherapy; ET – endocrine therapy; i – inhibitors; ER – estrogen receptor; IT – immunotherapy; ORR – overall response rate; PFS – progression-free survival; SERD – selective estrogen receptor downregulator.

Table 1. CDK4/6i in combination with biological agents or immunotherapy for luminal ABC.
(NCT03056755) was initiated, to test the efficacy of alpelisib plus ET after progressing on CDK4/6-inhibitors + ET.

Taselisib is a selective PI3K-inhibitor (PI3K) targeting alpha, delta, and gamma isoforms. The combination of taselisib plus fulvestrant was investigated versus fulvestrant alone in the phase 3 SANDPIPER trial [25], showing a significant but small mPFS increase in the combination arm (mPFS 7.4 vs 5.4 months; HR 0.70; 95% CI not provided; p < 0.01).

Nevertheless, toxicity was important, leading to more taselisib discontinuations (17% vs 2%) and dose reductions (37% vs 2%), versus placebo. A phase 2 trial testing taselisib plus tamoxifen is ongoing (POSEIDON trial).

Buparlisib is a highly selective pan-class I PI3K inhibitor tested in combination with several ET. Preliminary results from the phase 2 BELLE-2 trial [26] showed a significant PFS improvement from the combination of buparlisib plus fulvestrant versus fulvestrant alone (6.9 vs 5 months; HR 0.78; 95% CI 0.67–0.89; p < 0.001), with a favorable trend in OS (HR 0.87; 95% CI 0.74–1.02; p = 0.045) [27]. These results were confirmed in phase 3 BELLE-3 study [28], where mPFS was significantly higher in the combination arm (3.9 vs 1.8 months; HR 0.67, 95% CI 0.53–0.84; p < 0.01). Despite these results, the clinical development of buparlisib was stopped because of excessive toxicities. As high as 61% of patients in the buparlisib group experienced ≥G3 AEs, with elevated aminotransferases, hyperglycemia, and hypertension being the most frequent.

Capivasertib is an orally available pan-AKT inhibitor, for which efficacy data have been recently published. The phase 2 FAKTION trial [29] enrolled patients with luminal ABC pretreated with AI, randomizing them to receive fulvestrant with or without capivasertib. Patients were stratified according to PIK3CA and PTEN status. mPFS was 10.3 months for capivasertib versus 4.8 months for placebo (HR 0.58; 95% CI 0.39–0.84; p < 0.01), and median OS was 26 months for capivasertib compared to 20 months for placebo (HR 0.59; 95% CI 0.34–1.05; p = 0.071). However, the combination of fulvestrant and capivasertib in AKT-mutated cancers was not investigated in this trial. The most common ≥G3 AEs were hypertension (32% vs 24%), diarrhea (14% vs 4%), and fatigue (1% vs 4%), and two deaths were possibly related to the study regimen.

2.3. Histone deacetylase inhibitors

Epigenetic modifications are often implied in endocrine-resistance in ABC [30]. To overcome such resistance mechanism, several histone deacetylase (HDAC) inhibitors are under investigation.

Entinostat is a selective, oral, class I HDAC inhibitor. In luminal ABC, the combination of entinostat and exemestane has demonstrated to significantly improve mPFS versus exemestane alone in a phase 2 trial [31] (4.28 vs 2.27 months, HR 0.73; 95% CI not reported; p = 0.06). A randomized phase 3 trial testing the same combination is ongoing.

Tucidinostat is a subtype-selective HDAC-inhibitor entirely developed in China and already approved in this country. The phase 3 ACE trial [32] tested exemestane ± tucidinostat in ET-resistant postmenopausal patients, showing a significant PFS improvement (7.4 vs 3.8 months; HR 0.75; 95% CI 0.58–0.98; p = 0.033). Nevertheless toxicities were not negligible, and 48% of treatment interruptions were recorded in the experimental arm. Most frequently observed AEs were hematological, hypokalemia, and nausea.

2.4. FGFR-inhibitors

Fibroblast Growth Factor Receptor (FGFR) amplifications are detected in about 14% of BC, mainly in the luminal subtype [33]. FGFR-inhibition in luminal BC has been tested with both selective FGFR-inhibitors and multitarget tyrosine kinase inhibitors (TKI) with additional anti-angiogenic action.

AZD4547 is a highly selective inhibitor of FGFR1-3. The phase 1b/2a RADICAL trial [34] tested AZD4547 in combination with AIs, showing preliminary activity and safety in an FGFR-unselected population. The phase 2 GLOW trial instead enrolled only patients with FGFR1 polysomy or gene amplification, randomizing them to receive fulvestrant ±AZD4547. Data from this trial are still awaited.

Lucitanib is a dual inhibitor targeting VEGFR 1–3 and FGFR 1–3. The phase 1b INES trial [35] tested lucitanib in combination with fulvestrant in FGFR-unselected fulvestrant-pretreated luminal ABC, with some signals of activity (ORR 16.7%) but an unfavorable safety profile (high rate of G3-4 hypertension and fatigue). Further data were reported from the phase 2 FINESSE trial [36], testing lucitanib in FGFR1-altered and wild-type ER-positive/HER2-negative patients. Overall, 76 patients were enrolled, with modest activity (ORR 19%) demonstrated only in FGFR1 amplified patients, and significant cardiovascular toxicities (≥G3 hypertension in 66% of patients) related to the anti-angiogenic effect of lucitanib.

3. HER2-positive breast cancer

Since the approval of trastuzumab in 1998, several other anti-HER2 agents have been developed for HER2-positive ABC treatment, across diverse pharmacological classes. Until 2019, four of these agents had been FDA and/or EMA approved for the treatment of ABC: the mAbs trastuzumab and pertuzumab, the TKI lapatinib and the antibody-drug-conjugate (ADC) trastuzumab emtansine (TDM-1) [2]. Novel agents belonging to all of these classes are under development, and new agents with different mechanisms of action are showing activity in this context. In particular, novel anti-HER2 TKIs are showing encouraging results in combination with chemotherapy, especially in patients with central nervous system (CNS) disease, and novel ADCs are demonstrating impressive activity in highly pretreated HER2-positive ABC patients. Of note, the latter class of agents is showing potential activity in the treatment of HER2-low ABC, a wide category of patients for which no anti-HER2 agent has ever demonstrated activity. Such results are likely related to engineering improvements leading to the synthesis of ADCs with higher drug-to-antibody ratio (DAR) and cleavable linkers. These features allow the so-called bystander killing effect, namely the activity of the compound not only against cancer cells expressing the target but also against surrounding cells.
3.1. Anti-HER2 monoclonal antibodies

Margetuximab is an Fc-engineered anti-HER2 mAb, designed to increase affinity for the activating Fc receptor CD16A and decrease affinity for the inhibitory Fc receptor CD32B. Preliminary results from the randomized phase 3 SOPHIA trial of margetuximab + chemotherapy in pretreated HER2-positive (both hormone receptor-positive and -negative) ABC demonstrated a statistically significant improvement in PFS over trastuzumab + chemotherapy (mPFS 5.8 vs 4.9 months; HR 0.76; 95% CI 0.59–0.98 p = 0.033), which was more pronounced in patients with CD16A genotypes containing a 158 F allele (mPFS 6.9 vs 5.1 months; HR 0.68; 95% CI 0.52–0.90; p = 0.005) [37]. A preliminary analysis of OS was also recently reported, with an HR of 0.95 in the overall population (95% CI 0.69–1.31), and an HR of 0.82 for the genotype-restricted population (95% CI 0.58–1.17) [38]. Safety was comparable in both arms. OS data are still maturing, and will potentially clarify the ultimate clinical impact of the compound.

3.2. Anti-HER2 tyrosine kinase inhibitors

Neratinib is an irreversible pan-HER TKI, currently approved for the extended adjuvant treatment of HER2-positive early BC based on the results of the phase 3 ExteNET trial [39]. Various trials have tested the drug in the advanced setting. In the phase 2 NEfERT-T trial, neratinib failed to show a superior activity compared with trastuzumab when associated to paclitaxel, although a superior CNS activity was noted [40]. A promising CNS activity was also shown by the phase 2 TBCRC022 trial in ABC patients with brain metastases, with a CNS response rate ranging between 33% and 49% depending on previous TKI treatment [41]. Finally, data from the randomized phase 3 NALA trial were recently presented: compared with lapatinib and capecitabine, neratinib and capecitabine demonstrated an improved activity in terms of PFS, with a similar toxicity profile [42]. Overall, the main toxicity identified was diarrhea, ≥G3 in about 30% of the patients across the trials. Following these results, FDA approved the combination of neratinib and capecitabine for HER2-positive ABC pretreated with ≥ prior anti-HER2-based treatments.

Tucatinib is a HER2-selective TKI currently in the study for ABC, for which a promising activity was reported in early phase trials. In a phase 1b trial testing the combination of tucatinib + TDM1 in second line after trastuzumab and a taxane, an ORR of 48% was reported, with an acceptable toxicity profile [43]. A further phase 1b trial tested tucatinib in combination with trastuzumab and capecitabine, finding an ORR of 61% and a brain-specific ORR of 42%, with fewer EGFR-related AEs compared with other anti-HER2 TKIs [44]. These results guided the design of the randomized phase 2 HER2CLIMB trial, which tested the combination of capecitabine and trastuzumab with or without tucatinib in TDM1-pretreated HER2-positive ABC patients [45]. Results from this trial were recently published, showing a statistically significant improvement of PFS at 1 year from 12.3% to 33.1% (HR 0.54; 95% CI 0.42 to 0.71; p < 0.001) and a statistically significant improvement in OS from 17.4 months to 21.9 months in the study arm (HR 0.66; 95% CI 0.50 to 0.88; p = 0.005) [46]. ORR was also improved in the tucatinib arm, and the drug demonstrated a remarkable activity also in patients with brain metastasis at enrollment. There was a higher rate of ≥G3 diarrhea (12.9% vs 8.6%) and aminotransferase increase (5% vs 0.5%) in the study arm, with most of other toxicities being comparable. Based on these results, the compound has been recently granted Priority Review by FDA.

Poziotinib is an irreversible pan-HER TKI which has shown interesting activity for pretreated HER2-positive ABC patients. In a phase 2 trial conducted in South Korea, the compound achieved an ORR of 25% and a mPFS of 4 months, with diarrhea, stomatitis, and rash being the most common AEs [47]. Further trials are testing the compound in combination with TDM1 or in patients harboring EGFR/AR alterations.

Poziotinib is an irreversible pan-HER TKI for which encouraging data has recently been reported in pretreated HER2-positive ABC. A phase 3 trial conducted in China randomized 279 HER2-positive ABC patients to receive capecitabine ± poziotinib, finding an ORR (68% vs 16%) and PFS advantage in the poziotinib arm (11 vs 4 months; HR 0.18; 95% CI 0.13–0.26; p < 0.001) [48]. Furthermore, in a phase 2 trial enrolling 128 HER2-positive ABC patients, the capecitabine + poziotinib combination achieved a higher ORR (78% vs 57%, p 0.01) and PFS (18 vs 7 months; HR 0.36; 95% CI, 0.23–0.58; p < 0.01) compared with capecitabine + lapatinib, with a comparable safety profile [49]. The randomized phase 3 PHOEBE is currently testing the same combinations on a larger study population.

3.3. Anti-HER2 antibody-drug conjugates

Trastuzumab deruxtecan is a HER2-targeting mAb conjugated with a topoisomerase I inhibitor (DXd), characterized by a high DAR (7–8) and an enzymatically cleavable linker, which enables an effective bystander effect. A single-group phase 2 trial tested the compound in 184 highly pretreated (median of 6 prior lines) HER2-positive ABC patients, showing an impressive ORR of 60.9%, a DCR of 97.3%, and a mPFS of 16.4 months [50]. Efficacy was seen in all patient subgroups, including patients with CNS disease, ER+ disease, and prior treatment with TDM1. Estimated OS at 1 year was 86%, while mOS was not reached. The main ≥G3 toxicities were neutropenia (20.7%), anemia (8.7%), and nausea (7.6%), likely related to the chemotherapy backbone. However, interstitial lung disease (ILD) emerged as a potentially severe AE, with 13.6% of the patients experiencing any-grade ILD, and four deaths related to the toxicity. Following the report of fatal cases of ILD, a robust monitoring and management plan has been established for all trastuzumab deruxtecan studies, with prompt detection and treatment of ILD, and study treatment discontinuation in symptomatic cases.

Of note, the compound showed relevant activity also in HER2-low patients (HER2 IHC 1+ or 2+ with negative ISH assay), a subgroup of patients for whom no anti-HER2 therapy is currently approved. Indeed, the conjugate was tested in a phase 1 trial enrolling 54 highly pretreated HER2-low ABC patients, finding an ORR of 37%, a mPFS of 11.1 months, and...
a mOS of 29.4 months [51]. According to the promising activity seen in early phase trials, three phase 3 trials have been initiated, one of which in HER2-low patients [52]; moreover, two phase 1b trials are testing the drug in combination with anti-PD1 antibodies. However, the impressive data observed in the abovementioned phase 2 trial were sufficient to prompt FDA accelerated approval of trastuzumab deruxtecan for pretreated HER2-positive ABC patients in early 2020.

Trastuzumab duocarmazine is a HER2-targeting mAb conjugated to a potent duocarmycin payload (vc-seco-DUBA) through a cleavable linker, with a DAR of 2.8. Results from the phase 1 trial testing the compound in multiple HER2-expressing solid tumor patients revealed a promising ORR of 33% and mPFS of 7.6 months in HER2-positive ABC patients [53]. BC patients were highly pretreated, with a median of 6 previous treatments. In analogy with trastuzumab deruxtecan, trastuzumab duocarmazine showed activity also in HER2-low ABC, with an ORR ranging between 28% and 40% depending on hormone receptors status [54]. ≥G3 toxicities occurred in 35% of the patients, mainly consisting of neutropenia, fatigue, and conjunctivitis. The phase 3 TULIP trial is currently ongoing, comparing trastuzumab duocarmazine to treatment of physician choice in HER2-positive BC.

3.4. Anti-HER2 bispecific antibodies

ZW25 is a bispecific/biparatopic antibody targeting two different domains of HER2 (ECD2/ECD4). After several in vivo studies demonstrating activity of the compound in both HER2-positive and HER2-low expressing models, a phase 1 trial was initiated. Seventeen highly pretreated HER2-positive ABC patients were enrolled, with 13 being evaluable for response [55]. In this cohort, PR rate was 46%, with a DCR of 54%. Toxicity profile was manageable, with only G1-2 AEs consisting of diarrhea and infusion reactions. Notably, by linking an auristatin payload to ZW25, the new compound ZW49 was derived, combining the mechanisms of action of ADCs and bispecific antibodies. The antibody is currently being tested in a phase 1 trial (NCT03821233).

3.5. Immunotherapy in HER2-positive breast cancer

Together with demonstrating a critical role in TNBC, immune checkpoint inhibitors (ICPI) are being tested in HER2-positive disease, with some signals of activity. The phase 1b/2 PANACEA trial [56] tested the combination of trastuzumab and pembrolizumab in pretreated patients with HER2+ ABC. An ORR of 15% was achieved in the PDL1-positive population, whereas no responses were observed among PD-L1 negative patients. mPFS was similar between the two groups (2.7 and 2.5 months, respectively). OS data are still immature, but preliminary results underlined a possible benefit for patients with PDL1-positive tumors.

The KATE2 trial [57,58] investigated instead the combination of TDM1 plus atezolizumab/placebo, identifying a possible treatment benefit restricted to PDL1-positive tumors (mPFS 8.5 vs 4.1 months; HR 0.60; 95% CI 0.32–1.11; mOS not reached in both arms; HR 0.55; 95% CI 0.22–1.38). Several other trials combining anti-HER2 agents and ICPI are ongoing, also in combination with chemotherapy as first-line treatment (NCT03125928).

3.6. CDK4/6-inhibitors

Various CKD4/6-inhibitors are being investigated in different combination for HER2-positive BC (Table 2). Indeed, preclinical evidence show that CDK4/6-inhibitors could result synergic with HER2-inhibition [59], together with reverting resistance to anti-HER2 agents [60]. Relevant data with two of these combinations have been recently reported.

Palbociclib was tested in combination with trastuzumab ± letrozole in the SOLT1-PATRICIA phase 2 study, enrolling pre-treated HER2+ patients [61]. At a preliminary analysis on 45 patients, the combination showed to be safe and active, particularly in the luminal subtype by PAM50, with a better clinical benefit rate (73% vs 31%) and mPFS (12.4 vs 4.1 months, HR 0.37; 95% CI not reported; p 0.052) compared with non-luminal tumors.

Abemaciclib was studied in combination with trastuzumab and fulvestrant in the phase 2 MonarchHER trial for pretreated triple-positive (hormone receptor-positive/HER2-positive) patients [62]. At a recent report on 237 patients, the triplet arm showed a statistically significant improvement in mPFS (8.3 vs 5.7 months; HR 0.67; 95% CI 0.45–1.003; p 0.025) and ORR (32.9% vs 13.9%, p 0.004) over the chemotherapy + trastuzumab arm, with a comparable safety profile, making of this combination an appealing option in the triple-positive disease. Despite these promising results, it must be noted that the third study arm combining abemaciclib plus trastuzumab did not show superiority over chemotherapy plus trastuzumab. Since there was no study arm with trastuzumab plus fulvestrant alone, the influence of abemaciclib to the observed PFS advantage remains unclear.

4. Triple-negative breast cancer

Historically, the denomination of TNBC used to imply the absence of known druggable targets for this subset of BCs, which is the reason why this cancer’s systemic treatment has mostly relied on chemotherapies for decades. Nonetheless, recent advancements in drug development lead to the approval of the first immunotherapy for PDL1-positive advanced TNBC and two oral PARP-inhibitors for gBRCA-mutated ABCs. Moreover, several other targeted agents are demonstrating activity in this subtype of BC, challenging the classification itself. In this context, one emerging entity is HER2-low expressing TNBCs, for which various drugs are showing encouraging activity, as well as TNBC expressing TROP2, LIV1, and other targetable antigens.

4.1. Immune checkpoint inhibitors

Several anti-PD(L)1 antibodies have shown various degrees of activity in advanced TNBC. In particular, higher activity has been described in first-line treatment, in combination with chemotherapy and in patients expressing PD-L1 on tumor-infiltrating immune cells [63]. For the purpose of this review, due to its recent approval, only atezolizumab will be reviewed.
<table>
<thead>
<tr>
<th>Trial – NCT</th>
<th>Estimated enrollment</th>
<th>Study population</th>
<th>Study arm(s)</th>
<th>Primary endpoint</th>
<th>CT.gov status</th>
</tr>
</thead>
<tbody>
<tr>
<td>NCT03709082</td>
<td>I/II 62</td>
<td>ER+/HER2+ABC pretreated with both trastuzumab and taxanes</td>
<td>Palbociclib (75, 100 or 125 mg) + letrozole + T-DM1</td>
<td>ORR</td>
<td>Recruiting</td>
</tr>
<tr>
<td>NCT02448420 SOLTIPATRICIA trial</td>
<td>II 232</td>
<td>ER+/HER2+ABC pretreated with 2–4 lines of therapy including trastuzumab or another anti-HER2</td>
<td>Palbociclib + trastuzumab + ET vs TPC (T-DM1 or CT+trastuzumab)</td>
<td>PFS</td>
<td>Recruiting</td>
</tr>
<tr>
<td>NCT02947685 PATINA</td>
<td>III 496</td>
<td>ER+/HER2+ABC without evidence of PD after 4–8 cycles of induction therapy with trastuzumab + CT (taxane or vinorelbine)</td>
<td>Palbociclib + anti-HER2 (trastuzumab/pertuzumab) + ET (AI or fulvestrant) vs anti-HER2 (trastuzumab/pertuzumab) + ET (AI or fulvestrant) after induction treatment</td>
<td>PFS</td>
<td>Recruiting</td>
</tr>
<tr>
<td>NCT03054363</td>
<td>I/II 25</td>
<td>ER+/HER2+ABC as 1st-3rd line of therapy (up to 1 line of CT or anti-HER2 or anti-HER2+CT allowed; and up to 1 line of ET allowed); no prior treatment with anti-EGFR TKIs or anti-HER2 TKIs or CDK4/6i allowed</td>
<td>Palbociclib (100 or 125 mg) + letrozole + tucatinib (250 or 300 mg)</td>
<td>Safety, PFS</td>
<td>Recruiting</td>
</tr>
<tr>
<td>NCT03304080</td>
<td>I/II 36</td>
<td>ER+/HER2+ABC as 1st line of therapy</td>
<td>Palbociclib + trastuzumab + pertuzumab + anastrozole</td>
<td>Safety, CBR</td>
<td>Recruiting</td>
</tr>
<tr>
<td>NCT03913234</td>
<td>I/II 95</td>
<td>ER+/HER2+ABC as 1st line of therapy</td>
<td>Ribociclib (200, 400 or 600 mg) + letrozole + trastuzumab</td>
<td>Safety, CBR</td>
<td>Recruiting</td>
</tr>
<tr>
<td>NCT02657343 Cohort C</td>
<td>I/II 26</td>
<td>ER+/HER2+ABC progressing on trastuzumab, pertuzumab and T-DM1 (maximum 5 prior lines of therapy; prior fulvestrant allowed)</td>
<td>Palbociclib + trastuzumab + fulvestrant</td>
<td>PFS</td>
<td>Not yet recruiting</td>
</tr>
<tr>
<td>NCT02675231 MonarchHER</td>
<td>II 225</td>
<td>ER+/HER2+ABC after prior exposure to at least two anti-HER2 regimens for ABC</td>
<td>Abemaciclib + trastuzumab + fulvestrant versus Abemaciclib + trastuzumab versus Trastuzumab + CT</td>
<td>Safety, CBR</td>
<td>Active, not recruiting</td>
</tr>
<tr>
<td>NCT03846583</td>
<td>I 53</td>
<td>ER+/HER2+ABC with CNS metastasis CT (prior CDK4/6i not allowed)</td>
<td>Abemaciclib + trastuzumab + tucatinib + AI</td>
<td>PFS</td>
<td>Active, not recruiting</td>
</tr>
<tr>
<td>NCT01057133*</td>
<td>I 198</td>
<td>ER+/HER2+ABC progressing on at least one line of CT (prior CDK4/6i not allowed)</td>
<td>Abemaciclib + trastuzumab + pertuzumab + ET + loperamide</td>
<td>Safety</td>
<td>Recruiting</td>
</tr>
</tbody>
</table>

*Only the study arm enrolling triple-positive ABC is here considered.

ABC – advanced breast cancer; AI – aromatase inhibitor; CNS – central nervous system; CBR – clinical benefit rate; CT – chemotherapy; ER – estrogen receptor; ET – endocrine therapy; ORR – overall response rate; PD – progressive disease; PFS – progression-free survival.
Nonetheless, we have data available on the activity of several other anti-PD(L)1 agents, including nivolumab, avelumab, durvalumab, and pembrolizumab [64]. Moreover, for the latter agent, a randomized phase 3 trial is ongoing to determine its activity in combination with chemotherapy.

Atezolizumab is an anti-PD-L1 antibody able to prevent PD-L1 interaction with the receptors PD-1 and B7-1, reversing T-cell suppression. After demonstrating a good safety profile and a variable activity in early phase trials, the large phase 3 IMPassion130 trial was initiated, randomizing 451 advanced TNBC patients to receive nab-paclitaxel with atezolizumab or placebo as first-line treatment [65]. The combination ultimately showed a statistically significant prolongation of PFS, both in PD-L1-positive patients (7.5 vs 5 months; HR 0.62; 95% CI 0.49–0.78; p < 0.001) and in the intention-to-treat population (7.2 vs 5.5 months, HR 0.80; 95% CI 0.69–0.92; p = 0.002). Due to the design of the trial, no statistically significant OS benefit could be proven; nonetheless, a numerical advantage of 7 months [66] was reported in PD-L1 positive patients. The combination was well tolerated, with a 49% G3-4 AE rate (vs 42% in the control arm). Based on these results, the regimen was approved as first-line treatment of advanced PD-L1-positive TNBC, becoming the first immunotherapy approval for the treatment of BC [67]. Numerous trials are testing other atezolizumab combinations in the same setting, in order to determine the best regimen in first-line treatment of advanced TNBC. As an example, preliminary results from a phase 1b trial testing the triplet of a taxane + atezolizumab + ipatasertib (AKT inhibitor) demonstrated an impressive 73% ORR irrespective of PD-L1 status, with a manageable toxicity [68]. Data regarding further combinations are awaited.

A particular mention is needed for immune induction strategies in advanced TNBC. A recent report from the ongoing phase 2 TONIC trial showed interesting clinical and translational outcomes of a 2-week low-dose induction with chemotherapy (cisplatin, doxorubicin, or cyclophosphamide) or radiotherapy before starting immunotherapy with the anti-PD1 agent nivolumab [69]. In particular, the highest response rates were obtained with cisplatin (23%) and doxorubicin (35%) induction, as well as an upregulation of immune-related genes involved in PD-L1 and T cell cytotoxicity pathways in the same cohorts.

4.2. PARP-inhibitors

Since the first preclinical reports, the sensitivity of BRCA1- and BRCA2-mutant BC cells to PARP-inhibitors has been extensively studied, leading to the development of multiple PARP-inhibitors [70]. These inhibitors vary in their activity and toxicity, mostly due to their PARP trapping potency. Two PARP-inhibitors are currently approved for the treatment of gBRCA-mut HER2-negative BC, regardless of hormone receptors expression.

Olaparib is an oral PARP-inhibitor with an average PARP trapping potency. The compound was compared to standard chemotherapy (capecitabine, eribulin, or vinorelbine) in the phase 3 OlympiAD trial, enrolling gBRCAmut HER2-negative ABC patients [71]. The trial demonstrated a PFS benefit for the olaparib arm (7 vs 4.2 months; HR 0.58; 95% CI 0.43–0.80; p < 0.001) as well as a higher response rate (ORR 60% vs 29%), with a better toxicity profile compared to chemotherapy. Most common AEs were hematological and gastrointestinal, more commonly G1-2. Based on these data, olaparib received FDA-approval for the treatment of gBRCA-mut HER2-negative ABC who have been previously treated with chemotherapy.

Talazoparib is an oral PARP-inhibitor with a high PARP trapping potency, about 100 times greater than that of olaparib [72]. Talazoparib was compared to standard chemotherapy (capecitabine, eribulin, gemcitabine, or vinorelbine) in the phase 3 EMBRACA trial, for gBRCA-mut HER2-negative ABC patients [73]. Patients in the talazoparib arm experienced a significantly longer mPFS (8.6 vs. 5.6 months; HR 0.54; 95% CI 0.41–0.71; p < 0.001) and response rate (ORR 62.6% vs 27%, p < 0.001) compared with the control arm. However, this was achieved at the expense of a higher toxicity rate, mostly hematological, with 55% of the patients experiencing G3-4 hematological AEs in the talazoparib arm compared with 38% in the control arm. Following these results, talazoparib was approved by FDA for the treatment of germline BRCA-mutated HER2-negative ABC.

Interestingly, data on the combination of PARP-inhibitors and immunotherapy with anti-PD(L)1 mAbs are emerging. In the phase 2 MEDIOLA trial, 34 gBRCA-mut HER2-negative ABC patients were treated with olaparib and durvalumab [74]. Of the 30 patients evaluable for response, 19 achieved a response, for an ORR or 63%, and a mPFS of 8.2 months. Of note, response rate tended to be higher in less pretreated patients, consistently with other immunotherapy trials in ABC. Slightly different was the design of the phase 2 TOPACIO trial, which tested the combination of niraparib and pembrolizumab in patients with advanced TNBC, irrespective of BRCA mutation status [75]. Preliminary results were recently reported and showed an ORR of 11% in BRCA-wild type patients, which raised to 47% in BRCA-mutant patients. The combination was tolerable, with mostly hematological AEs.

Finally, results from a randomized phase 3 trial testing the combination of the PARP-inhibitor veliparib with carboplatin and paclitaxel in gBRCA-mut ABC patients were recently presented [76]. Veliparib showed to significantly improve mPFS (14.5 vs 12.6 months, p = 0.002), with comparable AEs. Nevertheless, it must be noted that the study allowed for a maintenance therapy with veliparib in absence of disease progression, so it is not clear if the combined therapy with chemotherapy is needed for this PFS improvement. ORR and OS were not significantly different in the two arms.

Although not immediately practice changing, these data confirm the feasibility of combining PARP-inhibitors with chemotherapy, despite their overlapping toxicity profile.

4.3. Antibody-drug conjugates

Besides ADCs targeting low HER2 expressions, novel ADCs against several other targets are being investigated in TNBC. Differently from HER2, such targets are not necessarily involved in oncogenic pathways, since the main anti-tumoral activity is provided by the chemotherapy payload carried by the ADC. Target antigens need instead to be tumor-specific (or
immunotherapy and targeted therapy are discussed. In both HER2-positive and TNBC (Table 3).

Ladiratuzumab Vedotin is an anti-LIV-1 antibody conjugated via a cleavable linker to an auristatin payload. LIV-1 is a transmembrane protein expressed in about 90% of ABC, with a much lower expression in normal tissues. In a phase 1 trial, 63 advanced TNBC patients received ladiratuzumab vedotin; LIV-1 tumor expression was required for the enrollment [78]. The compound was safe and well tolerated, with most of G3-4 AEs being hematological; of note, all-grade alopecia and peripheral neuropathy were reported in 36% and 20% of the patients, respectively. An ORR of 25% was achieved, with a DCR of 35%. Various trials testing the compound in monotherapy and in different combinations are currently ongoing.

Additional ADCs for which encouraging early results were reported are: the anti-PTK7 ADC PF-7020, which showed an ORR of 21% in pretreated TNBC patients in a phase 1 trial [79]; the anti-EFNA4 ADC PF-06647263, showing a 10% ORR in BC patients in a phase 1 trial [80]; the anti-gpNMB ADC glembatumumab vedotin, which showed an ORR of 16% (vs 15% with capecitabine) in gpNMB-overexpressing TNBC in a randomized phase 2b trial [81]. Several other ADCs are under investigation in both HER2-positive and TNBC (Table 3).

5. Future directions

A variety of novel biologic treatment approaches are being investigated in the treatment of all subtypes of ABC (Figure 2). In the next paragraphs, some recent advancements in BC immunotherapy and targeted therapy are discussed.

5.1. Immunotherapy beyond ICPI: adoptive cell therapy

The term ‘adoptive cell therapy’ refers to a relatively new immunotherapy technique based on adoptive transfer of T cells engineered ex-vivo to have chimeric antigen receptors (CAR) or tumor-infiltrating lymphocytes (TILs) targeting tumor antigens. Few pieces of evidence are available about the efficacy of these treatments in solid tumors, including BC.

CAR-T cells are genetically modified autologous T-cells that present on their surface chimeric receptors specific for tumor-associated antigens (TAAs), along with various costimulatory molecules.

HER2, mesothelin, and ROR1 are the main TAAs under investigation for CAR-T therapy. HER2- and mesothelin-targeted CAR-T showed efficacy in both in vitro cell lines and mice models [82–85], but at present few evidences [86,87] are available about their activity in patients with ABC. Some early clinical trials recruiting also BC patients are ongoing (NCT02792114, NCT03740256, NCT03198052, NCT03696030, NCT03747965, NCT03545815, NCT03615313). ROR1-targeted CAR-T cells are also being tested in clinical trials, and a preliminary report on 4 TNBC patients showed the treatment to be safe and potentially active [88].

Even if the rationale is strong, many questions need to be solved. The major challenge associated to CAR-T therapy is related to the rarity of ‘real’ tumor antigens, and consequently to the ‘on-target, off-tumor’ toxicity associated to antigen expression in normal tissues [89]. Moreover, TAAs are frequently subjected to immune escape, a well-described mechanism of resistance that consists of antigenic shift and production of new antigens no more recognized by specific CAR-T cells. Issues related to limited survival of the CAR-T cells, to their inefficient homing and to resistance to immune-suppressive tumor microenvironment will also need to be addressed.

TILs therapy instead relies on isolation of antitumor T lymphocytes infiltrating the tumor stroma, their expansion ex vivo and re-infusion. Before being re-infused, TILs are co-cultured with autologous dendritic cells previously engineered to recognize specific tumor antigens selected by tumor DNA sequencing.

This strategy has demonstrated to be effective in tumors with high levels of mutations and high TILs, such as melanoma [90]. Thanks to advances in TILs isolation, identification of tumor mutations and new cellular engineering techniques, TILs therapy has recently achieved significant results also in epithelial cancers, including BC. Nevertheless, most of these results are presented as single case reports [91]. Designing and conduction of clinical trials for such complex and ultra-personalized therapies is faced with many issues and costs, requiring unique expertise and laboratory infrastructures. A phase 2 clinical trial recruiting several advanced tumor types, including ABC, is ongoing at the National Cancer Institute (NCT01174121).

5.2. Anti-HER3 agents

Enhanced expression of HER3 has been reported in 50–70% of BC, in which it seems to represent a poor prognostic factor. HER3-overexpression has been associated to endocrine resistance in luminal BC [92], and with poor sensitivity to anti-HER2 agents [93] in HER2-amplified BC.

Several anti-HER3 monoclonal and bispecific Abs have been developed in order to overcome this resistance. Patritumab (U3-1287/A888), Seribatumumab (MM-121), and Lumretuzumab (RG7116, RO-5479599) are all anti-HER3 mAb tested in BC.

In HER2-amplified ABC the combination of patritumab plus trastuzumab and paclitaxel demonstrated to be safe and active, with an ORR of 38.9% [94]. Seribatumab has been investigated both in combination with paclitaxel in HER2-negative ABC and with ET in luminal ABC. Data about the combination with exemestane are available [95], showing a favorable trend in prolonging PFS and a significant increased OS. Lumretuzumab has been
<table>
<thead>
<tr>
<th>Drugs</th>
<th>Payload</th>
<th>Target</th>
<th>Trial – NCT</th>
<th>Phase</th>
<th>Estimated enrollment</th>
<th>Study population</th>
<th>Primary endpoint</th>
<th>CT.gov status</th>
</tr>
</thead>
<tbody>
<tr>
<td>A166</td>
<td>undisclosed cytotoxic agent</td>
<td></td>
<td>NCT03602079</td>
<td>I/I</td>
<td>82</td>
<td>Advanced HER2+ solid tumors, without other therapeutic options available</td>
<td>Safety, ORR</td>
<td>Recruiting</td>
</tr>
<tr>
<td>ALT-P7</td>
<td>monomethyl auristatin E</td>
<td></td>
<td>NCT03281824</td>
<td>I</td>
<td>30</td>
<td>HER2+ ABC who have progressed on previous trastuzumab-based therapy</td>
<td>Safety</td>
<td>Enrolling by invitation Recruiting</td>
</tr>
<tr>
<td>ARX788</td>
<td>monomethyl auristatin F</td>
<td></td>
<td>NCT03255070</td>
<td>I</td>
<td>60</td>
<td>Advanced HER2+ solid tumors, without other therapeutic options available (BC must have received trastuzumab)</td>
<td>Safety, ORR</td>
<td>Recruiting</td>
</tr>
<tr>
<td>DHES0815A</td>
<td>pyrrolo[2,1-c][1,4]-benzodiazepine monoamide (PBD-MA)</td>
<td></td>
<td>NCT03451162</td>
<td>I</td>
<td>14</td>
<td>HER2+ ABC relapsed/refractory to established therapies</td>
<td>Safety</td>
<td>Active, not recruiting</td>
</tr>
<tr>
<td>MED4276</td>
<td>tubulysin</td>
<td></td>
<td>NCT02576548</td>
<td>I</td>
<td>47</td>
<td>HER2+ ABC or AGC relapsed/refractory to established therapies (BC must have received trastuzumab, pertuzumab and T-DM1)</td>
<td>Safety</td>
<td>Completed (no results posted)</td>
</tr>
<tr>
<td>PF-06804103</td>
<td>undisclosed cytotoxic agent</td>
<td></td>
<td>NCT03284723</td>
<td>I</td>
<td>124</td>
<td>HER2+ ABC or AGC resistant to standard therapy or for which no standard therapy is available</td>
<td>Safety</td>
<td>Recruiting</td>
</tr>
<tr>
<td>AB-3A4</td>
<td>mertansine</td>
<td>EGFR</td>
<td>NCT03094169</td>
<td>I/IIa</td>
<td>90</td>
<td>EGFR-overexpressing squamous histology NSCLC, HNSCC or TNBC refractory to standard therapy, or for which no standard therapy is available (phase 2a)</td>
<td>Safety</td>
<td>Recruiting</td>
</tr>
<tr>
<td>BA3021 (CAB-ROR2)</td>
<td>undisclosed cytotoxic agent</td>
<td>ROR2</td>
<td>NCT03504488</td>
<td>I/II</td>
<td>120</td>
<td>Locally advanced unresectable or metastatic NSCLC, TNBC or STS refractory to standard therapy or for which no standard therapy is available (dose expansion phase)</td>
<td>Safety, ORR</td>
<td>Recruiting</td>
</tr>
<tr>
<td>BT1718</td>
<td>mertansine</td>
<td>MT1-MMP</td>
<td>NCT03486730</td>
<td>I</td>
<td>130</td>
<td>High MT1-MMP expressing TNBC or NSCLC refractory to standard therapy or for which no standard therapy is available (dose expansion phase)</td>
<td>Safety</td>
<td>Recruiting</td>
</tr>
<tr>
<td>PF-06647020 (Cofetuzumab pelidotin)</td>
<td>auristatin-0101</td>
<td>PTK7</td>
<td>NCT02222922</td>
<td>I</td>
<td>135</td>
<td>Locally advanced unresectable or metastatic TNBC (PTK7 moderately high to high expression), NSCLC (moderate to high PTK7 expression) and OC (unselected for PTK7 expression) resistant to standard therapy or for whom no standard therapy is available</td>
<td>Safety</td>
<td>Active, not recruiting</td>
</tr>
<tr>
<td>MEN1309</td>
<td>ravtansine</td>
<td>CD205</td>
<td>NCT04064359</td>
<td>I</td>
<td>70</td>
<td>Recurrent and/or metastatic CD205+ solid tumors and CD205+ HER2-negative ABC</td>
<td>Safety</td>
<td>Recruiting</td>
</tr>
<tr>
<td>MORAb-202</td>
<td>eribulin</td>
<td>FRA</td>
<td>NCT03386942</td>
<td>I</td>
<td>55</td>
<td>Folate receptor α (FRA)-positive TNBC and Type 2 endometrial carcinoma progressed to chemotherapy</td>
<td>Safety</td>
<td>Recruiting</td>
</tr>
<tr>
<td>PCA-062</td>
<td>Not available</td>
<td>pCAD</td>
<td>NCT02375958</td>
<td>I</td>
<td>47</td>
<td>pCAD-positive TNBC or EC or HNSCC (independently from pCAD) refractory to standard therapy, or for which no standard therapy is available</td>
<td>Safety</td>
<td>Completed (no results posted)</td>
</tr>
<tr>
<td>SAR566658</td>
<td>ravtansine</td>
<td>CA6</td>
<td>NCT02984683</td>
<td>II</td>
<td>23</td>
<td>CA6-positive metastatic TNBC pretreated with 1–3 lines of chemotheraphy</td>
<td>ORR</td>
<td>Completed (no results posted)</td>
</tr>
<tr>
<td>SAR428926</td>
<td>ravtansine</td>
<td>LAMP1</td>
<td>NCT02575781</td>
<td>I</td>
<td>34</td>
<td>Locally advanced unresectable or metastatic patients with LAMP1-positive TNBC, prostate cancer, CRC, OC or NSCLC (dose expansion phase)</td>
<td>Safety</td>
<td>Completed (no results posted)</td>
</tr>
</tbody>
</table>


*This trial is enrolling HER-negative ABC (also luminal subtypes).
combined with paclitaxel and pertuzumab for the treatment of HER2-low/HER3+ ABC [96]. Observed ORR was high (55% and 38.5% in different dose-cohorts), but the therapeutic window was too narrow to allow for further clinical development.

However, the most encouraging signals to date come from the phase 1/2 study of U3-1402, an anti-HER3 ADC conjugated with a topoisomerase I inhibitor payload, with a high DAR (7:1 to 8:1). The compound was tested in 42 heavily pretreated HER3-positive (IHC score 2+/3+) ABC patients and showed a promising activity regardless of HER2-positivity [97]. In fact, only 16% of patients enrolled in the trial were HER2-positive, with the vast majority comprising hormone receptor-positive and TNBC patients. Forty-two patients were treated in the dose-expansion part of the trial, with an ORR of 42.9%, a mDCR of 90.5%, and a mPFS of 8.3 months. Antitumor activity was observed in all molecular subtypes, and treatment was moderately tolerated, with most common ≥G3 AEs being thrombocytopenia (35%), neutropenia (28%), leukopenia (21%), and anemia (16%).

6. Expert opinion

Significant advancements for the management of ABC have been achieved, as a result of better understanding of the molecular mechanisms underlying breast oncogenesis and resistance-generation to treatments. Indeed, the last decade has seen a progressive increase in the development and approval of new biological drugs for the treatment of all ABC subtypes, and today, in developed countries, most ABC patients receive a biologic agent as first-line treatment for their disease.

However, the extent of clinical benefit provided by such agents is highly variable and needs to be constantly weighted against the possible increase in toxicities. For instance, in the setting of luminal ABC, several attempts to combine ET with biological agents have been made, with various compounds being approved for this indication. Some of these agents, such as CDK4/6-inhibitors, have rapidly acquired a preeminent role in all guidelines, due to the favorable safety profile. Some others, such as everolimus, are still only partially implemented in everyday practice, due to the less manageable toxicities. The same applies for other ABC subtypes: for instance, while the first- and second-line treatments of HER2-positive ABC are well defined, several drugs are currently approved for pre-treated HER2-positive ABC, challenging clinicians in the choice of the most appropriate agent. In this framework, a promising tool may help to weight the clinical value of novel agents, namely the ESMO Magnitude of Clinical Benefit Scale (MCBS) [98], whose implementation could significantly help medical oncologists in the process of clinical decision-making.

Beside the relevant drug approvals in the recent past, a variety of novel compounds are showing encouraging results in all ABC subtypes, and promise to further improve outcomes of these patients. While some of these drugs represent pharmacological evolutions of previously approved agents (e.g. novel anti-HER2 TKIs), some others might pave the way for new paradigms in ABC treatment (Figure 3). In particular, novel ADCs are showing activity via the targeting of antigens which are not necessarily involved in oncogenic pathways. Key examples are trastuzumab deruxtecan and trastuzumab duocarmazine, showing activity in HER2-low non-amplified tumors, as well as Sacituzumab Govitecan, Ladiratuzumab Vedotin, and further ADCs targeting...
TAA expressed by TNBC cells. If early results from these compounds are confirmed, a considerable evolution of ABC treatment algorithms is expected.

Finally, the approval of biologic agents restricted to patients harboring predictive genetic alterations enhances the need to sequence ABC to choose the best treatment strategy. While HER2 status once was the only genomic information to guide the treatment algorithm, many more alterations are gaining importance to predict drug efficacy, such as PIK3CA and BRCA status; some others are showing potential in predicting drug resistance, such as ESR1 and PTEN. More in detail, by applying the ranking from ESMO Scale for Clinical Actionability of molecular Targets (ESCAT scale), around 40 recurrent driver alterations are found in BC [99]. Some of these (ERBB2 amplifications, BRCA1/2 mutations, PIK3CA mutations) are classified tier of evidence IA, which implies a high level of actionability and a proven benefit observed in large randomized trials. Additionally, tumor-agnostic alterations like NTRK fusions and microsatellite instability are ranked tier IC and are expected to be actionable based on studies enrolling a wide variety of cancers. The growing number of useful biomarkers is promoting big changes in BC diagnostics, with multigene NGS panels being already applied in several countries to comprehensively capture the complexity of each tumor with a single test.

However, the escalating costs of both diagnostic assays and novel drugs might represent an obstacle in their implementation, in particular in the framework of developing countries, where huge disparities in healthcare availability already exist.

In this complex scenario, the key to ensure sustainability for patients is to ensure the implementation based on the intrinsic value of assays and drugs, to make sure that value for the money is fulfilled.

In conclusion, novel biologic drugs and treatment strategies are currently revolutionizing ABC treatment algorithms, and an enlarging pipeline of promising agents is expected to provide increasing benefits to BC patients, as well as to promote the advancement of precision medicine in the treatment of BC.

Acknowledgments
We thank Dario Trapani for supporting proofreading.

Funding
This paper is not funded.

Declaration of interest
G Curigliano received honoraria for speaker, consultancy or advisory role from Roche, Pfizer, Novartis, Seattle Genetics, Lilly, Ellipses Pharma, Foundation Medicine, and Samsung. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Reviewer Disclosures
Peer reviewers on this manuscript have no relevant financial relationships or otherwise to disclose.
References

Papers of special note have been highlighted as either of interest (∗) or of considerable interest (∗∗) to readers.

3. Slamon DJ, Neven P, Chia S, et al. Overall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib. Ann Oncol. 2019;30.
21. Slamon DJ, Neven P, Chia S, et al. LBA7_PROoverall survival (OS) results of the phase III MONALEESA-3 trial of postmenopausal patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor 2-negative (HER2–) advanced breast cancer (ABC) treated with fulvestrant (FUL) ± r. Ann Oncol. 2019;30.
37. Rugo HS, Im S-A, Wright GLS, et al. SOPHIA primary analysis: A phase 3 (P3) study of margetuximab (M) + chemotherapy (C)
versus trastuzumab (T) + C in patients (pts) with HER2+ metastatic (met) breast cancer (MBC) after prior anti-HER2 therapies (Tx). J Clin Oncol. 2019;37:1000.


45. Paplomata E, Bachelot T, Mueller V, et al. 196TIPA randomized, double-blinded, controlled study of tucatinib (ONT-380) vs placebo in combination with capecitabine (C) and trastuzumab (T) in patients with previously treated HER2+ unresetable locally advanced or metastatic breast carcinoma (mBC) (HER2CLIMB, Ann Oncol. 2019;30.


- Of considerable interest due to the activity of the compound in the relevant unmet need of HER2-positive breast cancer patients with brain metastasis.


- Of considerable interest due to the unprecedented activity demonstrated by the compound in highly pretreated HER2–positive breast cancer patients.


- Of considerable interest due to the activity of the drug in the emerging subgroup of HER2-low breast cancer.


- Of considerable interest due to the activity of the compound in the emerging subgroup of HER2-low breast cancer.


